Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Lingdong Meng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9405-8120; OpenAlex author ID A5102002778. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2019: 2 papers · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 15

  1. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  2. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-025-07740-8↗
  3. The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer. First author DOI 10.1155/2023/6891636↗
  4. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  5. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  6. Suppressive effect of YY1-mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2022.13577↗
  7. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  8. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  9. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  10. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  11. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  12. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  13. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  14. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  15. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 13 shared papers, 2019–2025 · strength 1.83
  2. Wanli Ge · 13 shared papers, 2019–2025 · strength 1.78
  3. Peng Shen · 12 shared papers, 2019–2025 · strength 1.57
  4. Qun Chen · 12 shared papers, 2019–2025 · strength 1.55
  5. Xumin Huang · 12 shared papers, 2019–2025 · strength 1.54
  6. Hao Yuan · 9 shared papers, 2019–2025 · strength 1.12
  7. Yi Miao · 9 shared papers, 2019–2022 · strength 1.01
  8. Yi Miao · 4 shared papers, 2022–2025 · strength 0.73
  9. Guodong Shi · 5 shared papers, 2020–2025 · strength 0.67
  10. Taoyue Yang · 5 shared papers, 2021–2022 · strength 0.61
  11. Jingjing Zhang · 5 shared papers, 2019–2022 · strength 0.59
  12. Shouji Cao · 4 shared papers, 2020–2023 · strength 0.58
  13. Pengfei Wu · 5 shared papers, 2020–2022 · strength 0.56
  14. Lei Chen · 4 shared papers, 2019–2025 · strength 0.52
  15. Zipeng Lu · 4 shared papers, 2020–2022 · strength 0.47
  16. Baobao Cai · 2 shared papers, 2021–2022 · strength 0.25
  17. Min Tu · 2 shared papers, 2020–2022 · strength 0.23
  18. Kuirong Jiang · 2 shared papers, 2020 · strength 0.20
  19. Xiaole Zhu · 1 shared paper, 2023 · strength 0.18
  20. Qiang Li · 1 shared paper, 2023 · strength 0.18
  21. Yunpeng Peng · 1 shared paper, 2023 · strength 0.18
  22. Qun Chen · 1 shared paper, 2022 · strength 0.17
  23. Pengfei Wu · 1 shared paper, 2022 · strength 0.13
  24. Qun Chen · 1 shared paper, 2021 · strength 0.12
  25. Chuang Yang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.